Eisai (TKS: 4523)

Corporate Venture CapitalTokyo, Japaneisai.com

PharmaceuticalsHealthcareDementiaNeurologyOncologyGlobal Health

Eisai is a global pharmaceutical company based in Japan, operating under its 'human health care' (hhc) philosophy. The company specializes in research and development for therapeutic areas including neurology (specifically dementia) and oncology.

Visit eisai.com ↗

2
Portfolio companies on reccy: 0
Hiring now: 0
Open roles in the portfolio: Apr 2020
Latest portfolio round

Hiring now in the portfolio0

Apply on each company's site

None of their companies on reccy has an open role right now. Browse all neurotech roles

Portfolio on reccy2

From company funding records

CompanyLatest roundOpen roles

Recent rounds in the portfolio

Crunchbase funding records

Apr 2020
Darmiyan · Seed $6.4MLead
Aug 2019
Cogstate · Placement $939KLead

Stages they back

2 rounds on reccy

Seed1
Other1

Stated preferences

Merger/Acquisition

reccy insights

From their website

Thesis

human health care (hhc) concept
Focus on dementia and oncology as key therapeutic areas
Improving access to medicines in developing and emerging countries
Sustainability through human capital and environmental initiatives

What sets them apart

Deep focus on Alzheimer's and dementia research (LEQEMBI)
Commitment to the 'human health care' (hhc) philosophy
Proactive in treating Neglected Tropical Diseases (NTDs) like lymphatic filariasis

Portfolio highlights

LEQEMBI (lecanemab-irmb)
Tazverik (tazemetostat hydrobromide)
hhc Initiative 2025
Global Capability Centre in Visakhapatnam

Geographic focus

Japan
USA
India
Kenya
Global

About this page

Built from funding records for companies on reccy, deal records and the firm's own website. We list firms only, never individual investors. Updated Oct 12, 2026.

Browse neurotech jobs

Eisai (TKS: 4523)

Hiring now in the portfolio0

Portfolio on reccy2

Darmiyan

Cogstate

Recent rounds in the portfolio